Shopping Cart
Remove All
Your shopping cart is currently empty
Ficlatuzumab is a humanized monoclonal antibody that specifically targets and neutralizes the biological activity of human hepatocyte growth factor (HGF), by inhibiting HGF, Ficlatuzumab effectively blocks c-Met receptor-mediated downstream signaling pathways responsible for cancer cell proliferation, migration, and invasion, demonstrating applicable use for the treatment of squamous cell carcinoma.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $147 | - | In Stock | |
| 5 mg | $446 | - | In Stock | |
| 10 mg | $762 | - | In Stock | |
| 25 mg | $1,130 | - | In Stock | |
| 50 mg | $1,530 | - | In Stock |
| Description | Ficlatuzumab is a humanized monoclonal antibody that specifically targets and neutralizes the biological activity of human hepatocyte growth factor (HGF), by inhibiting HGF, Ficlatuzumab effectively blocks c-Met receptor-mediated downstream signaling pathways responsible for cancer cell proliferation, migration, and invasion, demonstrating applicable use for the treatment of squamous cell carcinoma. |
| In vitro | Ficlatuzumab (20 μg/mL, 24 hours) treatment of HNSCC cells can effectively reduce the migration and invasion of HNSCC cells promoted by tumor-associated fibroblast (TAF) culture medium, and can also reduce the epithelial-mesenchymal transition (EMT) and vimentin expression of HNSCC cells promoted by TAF. [1] |
| Cas No. | 1174900-84-5 |
| Color | Transparent |
| Appearance | Liquid |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.